Belite Bio, Inc. ADR (BLTE)
NASDAQ:BLTE
Top Page
Belite Bio, Inc. ADR
(NASDAQ:BLTE)
Select Model
Select Model
Rating:67Neutral
Price Target:
$184.00
▲(8.37% Upside)
Action:ReiteratedDate:04/05/26
Score is driven primarily by strong balance-sheet strength and a constructive earnings-call backdrop (Phase III success, defined NDA/launch timeline, and materially improved cash runway). This is tempered by pre-revenue financial performance with accelerating losses/cash burn, mixed technical signals, and limited support from traditional valuation metrics due to negative earnings and no dividend.
Positive Factors
Very strong balance sheet and cash runway
A large cash balance after the $402M offering provides multi-year runway to fund the NDA, commercialization build and ongoing R&D without immediate financing. This materially reduces short-term dilution and gives management flexibility to execute regulatory and launch plans over the next 2–3 years.
Negative Factors
Pre-revenue with accelerating cash burn
Despite a strong cash balance today, the company is pre-revenue and cash burn is accelerating as development and commercial activities scale. Continued negative operating and free cash flow imply financing risk over the medium term if milestones, pricing, or launch timing slip, pressuring resources.
Read all positive and negative factors
Positive Factors
Negative Factors
Very strong balance sheet and cash runway
A large cash balance after the $402M offering provides multi-year runway to fund the NDA, commercialization build and ongoing R&D without immediate financing. This materially reduces short-term dilution and gives management flexibility to execute regulatory and launch plans over the next 2–3 years.
Read all positive factors
Belite Bio, Inc. ADR (BLTE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.68B
Dividend YieldN/A
Average Volume (3M)64.23K
Price to Earnings (P/E)―
Beta (1Y)1.04
Revenue GrowthN/A
EPS Growth-73.27%
CountryUS
Employees25
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.38
Shares Outstanding39,965,313
10 Day Avg. Volume75,810
30 Day Avg. Volume64,229
Financial Highlights & Ratios
PEG Ratio-0.72
Price to Book (P/B)6.96
Price to Sales (P/S)0.00
P/FCF Ratio-144.35
Enterprise Value/Market Cap0.95
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-101.20
Forecast
1Y Price Target
$215.29Price Target Upside26.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-2.15
Revenue Forecast (FY)$30.00M
Belite Bio, Inc. ADR Business Overview & Revenue Model
Company Description
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead pr...
How the Company Makes Money
As a clinical-stage biopharmaceutical company, Belite Bio does not typically generate recurring revenue from product sales because its lead programs are in clinical development and not yet approved for commercial marketing. Its funding and cash in...
Belite Bio, Inc. ADR Earnings Call Summary
Earnings Call Date:Mar 02, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 19, 2026
Earnings Call Sentiment Positive
Overall the call was positive: the company reported a major clinical milestone (DRAGON Phase III success with 36% lesion-growth reduction), completed strong fundraising and set a clear regulatory and commercial timeline (rolling NDA in Q2 2026; target launch Q1 2027). The company is investing heavily in commercialization and R&D (reflected in sharply higher R&D and SG&A and wider net losses), and there are execution and timing risks around patient identification, pricing, ex-US filings and deprioritized programs. On balance the clinical success and cash runway materially de-risk the near-term path to approval and launch, outweighing the financial burn and execution risks described.Positive Updates
Phase III DRAGON Pivotal Success
DRAGON met its primary efficacy endpoint: a statistically significant and clinically meaningful 36% reduction in growth rate of upper lesion (definitely decreased autofluorescence) versus placebo.
Negative Updates
Rising R&D Expenses
Q4 R&D expenses increased to $14.6M from $7.3M (+100% YoY); non-GAAP Q4 R&D rose to $12.2M from $5.7M (+114% YoY). Full-year R&D was $45.4M vs $29.9M in 2024 (+52% YoY). Drivers: DRAGON II costs, PHOENIX costs, API manufacturing, timing of Australian R&D tax incentive and share-based compensation.
Read all updates
Q4-2025 Updates
Positive
Negative
Phase III DRAGON Pivotal Success
DRAGON met its primary efficacy endpoint: a statistically significant and clinically meaningful 36% reduction in growth rate of upper lesion (definitely decreased autofluorescence) versus placebo.
Read all positive updates
Company Guidance
The company guided that it plans a rolling NDA submission to the FDA in Q2 2026 (CSR to be finalized this month) following DRAGON top-line results showing a statistically significant, clinically meaningful 36% reduction in DDAF lesion growth versus placebo; DRAGON II (Japan-only) closed with ~72–75 subjects (target 60) and PHOENIX (GA) completed enrollment with 530 subjects, with an interim look for GA expected in H2 2026. Commercially, Belite is preparing to launch Tinlarebant by Q1 2027 with an initial U.S. field team of ~25–30 reps, expects to spend ~$200–250M on commercialization and ~$150M on R&D-related activities over the next three years, and continues to prioritize a U.S. filing before ex‑U.S. submissions; financials include cash, cash equivalents and U.S. Treasuries of $772.6M (up from $145.2M at 12/31/2024) following a $402M public offering, Q4 2025 R&D $14.6M (non‑GAAP $12.2M) and SG&A $13.5M (non‑GAAP $4.2M) with Q4 net loss $25.3M (non‑GAAP $13.6M), FY 2025 R&D $45.4M (non‑GAAP $36.2M) and SG&A $38.9M (non‑GAAP $9.1M) with FY net loss $77.6M (non‑GAAP $38.7M); other notable metrics include a U.S. Stargardt prevalence estimate of ~53,000 patients, an average rare‑disease price benchmark of ~$350,000 (company expects it could be higher), and a pediatric EMA plan (ages 3–11) starting April 2026 (2‑year study).Belite Bio, Inc. ADR Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
86
Very Positive
Cash Flow
32
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | -198.00K | -30.00K |
| EBITDA | -84.21M | -35.67M | -31.20M | -12.43M | -9.64M |
| Net Income | -77.61M | -36.14M | -31.63M | -12.65M | -9.67M |
Balance Sheet | |||||
| Total Assets | 780.56M | 152.13M | 94.64M | 44.27M | 18.35M |
| Cash, Cash Equivalents and Short-Term Investments | 492.42M | 145.15M | 88.16M | 42.09M | 17.34M |
| Total Debt | 429.00K | 537.00K | 886.00K | 866.00K | 31.81M |
| Total Liabilities | 10.07M | 6.31M | 4.21M | 2.77M | 33.44M |
| Stockholders Equity | 770.49M | 145.82M | 90.43M | 41.50M | -15.09M |
Cash Flow | |||||
| Free Cash Flow | -37.17M | -29.39M | -29.90M | -11.85M | -7.55M |
| Operating Cash Flow | -36.99M | -29.23M | -29.84M | -11.46M | -7.47M |
| Investing Cash Flow | -305.11M | -110.57M | -63.00K | -394.00K | -56.00K |
| Financing Cash Flow | 663.23M | 83.59M | 75.96M | 36.96M | -583.00K |
Belite Bio, Inc. ADR Technical Analysis
Positive
169.79
Price Trends
171.14
Negative
158.61
Positive
115.69
Positive
Market Momentum
-1.41
Negative
55.13
Neutral
76.79
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BLTE, the sentiment is Positive. The current price of 169.79 is above the 20-day moving average (MA) of 161.42, below the 50-day MA of 171.14, and above the 200-day MA of 115.69, indicating a neutral trend. The MACD of -1.41 indicates Negative momentum. The RSI at 55.13 is Neutral, neither overbought nor oversold. The STOCH value of 76.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BLTE.
Belite Bio, Inc. ADR Risk Analysis
Belite Bio, Inc. ADR disclosed 115 risk factors in its most recent earnings report. Belite Bio, Inc. ADR reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Belite Bio, Inc. ADR Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $1.60B | 23.98 | 19.84% | ― | 21.13% | 50.86% | |
69 Neutral | $3.75B | 51.87 | 11.48% | ― | 55.68% | ― | |
67 Neutral | $6.68B | -69.12 | -34.29% | ― | ― | -73.27% | |
66 Neutral | $5.90B | -17.18 | -50.66% | ― | 117.83% | -18.91% | |
54 Neutral | $2.49B | -34.27 | -7.31% | ― | -84.07% | -157.71% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $3.08B | -5.65 | -50.13% | ― | ― | -5.30% |
* Healthcare Sector Average
BLTE
Belite Bio, Inc. ADR
169.79
114.69
208.15%
DNLI
Denali Therapeutics
19.41
6.55
50.93%
KNSA
Kiniksa Pharmaceuticals
48.94
29.04
145.93%
BEAM
Beam Therapeutics
24.49
8.12
49.60%
HRMY
Harmony Biosciences Holdings
27.62
-1.45
-4.99%
CNTA
Centessa Pharmaceuticals
39.55
27.79
236.31%
Belite Bio, Inc. ADR Corporate Events
Belite Bio Posts 2025 Form 20-F Annual Report Online as Late-Stage Retinal Drug Trials Advance
Mar 31, 2026
Belite Bio, Inc., a clinical-stage developer of treatments for degenerative retinal diseases such as Stargardt disease type 1 and geographic atrophy in dry age-related macular degeneration, has advanced its lead oral candidate tinlarebant through ...
Belite Bio Posts 2025 Results as Tinlarebant Nears NDA Filing After Phase 3 Win
Mar 2, 2026
Belite Bio reported preliminary, unaudited fourth-quarter and full-year 2025 results on March 2, 2026, alongside a corporate update highlighting a pivotal year for its lead candidate tinlarebant. The company said positive topline data from the glo...
Belite Bio Completes Global Enrollment in DRAGON II Tinlarebant Trial for Stargardt Disease
Jan 27, 2026
On January 27, 2026, Belite Bio announced it has completed enrollment of 60 adolescent patients, including 15 in Japan, in its global Phase 2/3 DRAGON II trial of tinlarebant for Stargardt disease type 1, a 24‑month randomized, double‑...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.